☆ 4.6 Article

Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection

ECLINICALMEDICINE (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

Wan Ni Chia et al.

Summary: The study investigated the dynamics of neutralising antibody response in patients who have recovered from COVID-19, finding great variations and suggesting that predicting immune longevity can only be accurately determined at the individual level. The findings emphasize the importance of public health and social measures in the ongoing pandemic outbreak response, and may have implications for the longevity of immunity after vaccination.

LANCET MICROBE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Evolution of antibody immunity to SARS-CoV-2

Christian Gaebler et al.

Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Looking beyond COVID-19 vaccine phase 3 trials

Jerome H. Kim et al.

Summary: Following the announcement of COVID-19 vaccine efficacy in clinical trials, a comprehensive strategy is needed for global vaccination, including manufacturing, support, supply coordination, equitable distribution, and logistics. Additionally, addressing scientific questions to improve vaccine efficacy is crucial for ending the pandemic effectively and efficiently.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

S. F. Lumley et al.

Summary: In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Neutralizing antibody titres in SARS-CoV-2 infections

Eric H. Y. Lau et al.

Summary: In this study, researchers quantified SARS-CoV-2 specific neutralizing antibodies using plaque reduction neutralization (PRNT) assays on 195 patients in different disease states. They found that patients with severe disease had higher peaks of neutralizing antibody titres than patients with mild or asymptomatic infections, and that serum neutralizing antibody persists for over 6 months in most people.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Cell Biology

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Anthony T. Tan et al.

Summary: This study found that early induction of interferon-gamma (IFN-gamma) secreting SARS-CoV-2-specific T cells was present in patients with mild disease and accelerated viral clearance, while rapid induction and quantity of humoral responses were associated with an increase in disease severity. These findings highlight the importance of early functional SARS-CoV-2-specific T cells in both vaccine design and immune monitoring.

CELL REPORTS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Adam K. Wheatley et al.

Summary: The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Antibody, B cell, and T cell responses decline over the first 4 months post-infection, while S-specific IgG(+) memory B cells consistently accumulate. The study suggests that natural infection may only provide transient protection at a population level, highlighting the need for more immunogenic and durable vaccines.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Christian Holm Hansen et al.

Summary: The study investigated the protection against SARS-CoV-2 reinfection, with results showing an 80.5% protection rate for individuals previously infected. Even in the population aged 65 years and older, the protection rate against reinfection reached 47.1%, with no significant differences observed by gender or time since infection.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Nicole Doria-Rose et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Chang Liu et al.

Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.

CELL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Jackson S. Turner et al.

Summary: The study found that individuals who had recovered from mild SARS-CoV-2 infections showed rapid decline of serum anti-SARS-CoV-2 spike protein antibodies in the first 4 months after infection, followed by a more gradual decrease over the following 7 months but remaining detectable at least 11 months after infection. This suggests that mild infection with SARS-CoV-2 can induce robust antigen-specific, long-lived humoral immune memory in humans.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Ugur Sahin et al.

Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.

NATURE (2021)

添加到收藏夹

Article Immunology

Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants

Alberto Zani et al.

Summary: The study demonstrates that antibodies generated by the BNT162b2 vaccine can efficiently neutralize authentic viruses belonging to various SARS-CoV-2 lineages. Neutralization was highest for B.1.1.7 and B.1.525 lineages, while lower for B.1.351 and P.1 lineages compared to the B.1 lineage. The findings suggest that the BNT162b2 vaccine offers protection against the prevailing variants of SARS-CoV-2.

EMERGING MICROBES & INFECTIONS (2021)

添加到收藏夹

Article Immunology

Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection

Pyoeng Gyun Choe et al.

Summary: A study investigated antibody responses of 58 individuals 8 months after infection with severe acute respiratory syndrome coronavirus 2, showing high seropositivity rates for 3 out of 4 immunoassays used.

EMERGING INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Microbiology

Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera

Ranawaka A. P. M. Perera et al.

Summary: The surrogate virus neutralization test (sVNT) showed high sensitivity and specificity compared to the plaque reduction neutralization test (PRNT90) in human, canine, cat, and hamster sera. There was no cross-reactivity to other coronaviruses in both SARS-CoV-2 sVNT and PRNT90, except for cross-reactivity to SARS-CoV-1 in sVNT.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

添加到收藏夹

Article Immunology

Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods

Berislav Bosnjak et al.

Summary: The study found that COVID-19 convalescent patients have neutralizing antibodies in their serum that can effectively block the entry of SARS-CoV-2 virus. The levels of these neutralizing antibodies are correlated with the duration and severity of clinical symptoms, but not with age. The sVNT test is simpler, faster, and more cost-effective compared to the pVNT test, making it valuable for assessing the prevalence of neutralizing antibodies and selecting potential plasma donors for successful passive antibody therapy.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Serological assays for severe acute respiratory syndrome coronavirus 2 (BARS-CoV-2), March 2020

Ranawaka A. P. M. Perera et al.

EUROSURVEILLANCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Nina Le Bert et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani et al.

NATURE (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Chee Wah Tan et al.

NATURE BIOTECHNOLOGY (2020)

添加到收藏夹

Article Microbiology

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

Amin Addetia et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Seasonal coronavirus protective immunity is short-lasting

Arthur W. D. Edridge et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Letter Immunology

Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020

Paul K. S. Chan et al.

EMERGING INFECTIOUS DISEASES (2020)

添加到收藏夹

Review Immunology

The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine

Sophie A. Valkenburg et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹

Article Infectious Diseases

Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients

Lifeng Liu et al.

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2011)

添加到收藏夹

Review Immunology

Plasma cell development: From B-cell subsets to long-term survival niches

Kirsten A. Fairfax et al.

SEMINARS IN IMMUNOLOGY (2008)

添加到收藏夹

Article Medicine, General & Internal

Duration of humoral immunity to common viral and vaccine antigens

Ian J. Amanna et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.